RE: Questions for 22nd Presentation18 Apr 2021 11:09
Might get some splinters here, I agree with both. We’re in the dark on a few things so TL is right that as shareholders we’re not fully informed of what is going on. Comprehensive, especially honest, and even better, timely updates would be helpful. Good counter argument though jdt, if we were GSK we’d hear absolutely nothing. Case in point, Orasure, one update to say they’re developing a saliva test, next update it’s an AN test, latest update, they’ve submitted to the FDA with nothing between. We’ve not received much different to them.